We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.
NK (Common Stock) $4.85 + 0.10 (2.11%)
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Gl

Feb 13, 2018 | Press Releases

CULVER CITY, Calif.--(BUSINESS WIRE)--Feb. 13, 2018-- NantKwest Inc. (Nasdaq:NK

Read More

Dr. Patrick Soon-Shiong Presents at the 36th Annual J.P. Morgan Healthcare Conference

Jan 11, 2018 | Press Releases

Download Presentation (PDF)To watch the WebcastTo Listen to the Webcast

Read More

Nantworks To Present Healthcare And Biotechnology Platforms At 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018 In San Franci

Jan 05, 2018 | Press Releases

Announces a Record 25 Letters of Authorization to Proceed with Clinical Trials Coverin

Read More

Upcoming Events
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.